Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
Font Down Font Up

 
Par Pharmaceutical Turns To Profit In Q2 - Update
8/4/2009 3:40 PM  ET

RELATED NEWS
Par Pharma Receives Final Approval To Market Generic Ultram ER - Quick Facts
Par Pharmaceutical Q3 Profit Surges - Update
Par Pharma Q3 Profit Surges - Quick Facts
Par Pharma Companies Commences Modified Dutch Auction Tender Offer - Quick Facts
Par Pharma Gets FDA Approval To Market Diabetes Drug Nateglinide - Update
TOP MARKET NEWS
Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary
Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary
Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary
New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening
Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary
(RTTNews) -  Tuesday, Par Pharmaceutical Companies Inc. (PRX: News ), reported a swing to profit for the second quarter from a year ago helped by a significant surge in revenues, driven primarily driven by sales of its generic drug metoprolol succinate, equivalent to AstraZeneca's Toprol XL.

The Woodcliff Lake, New Jersey-based company posted a net income of $23.8 million or $0.71 per share for the quarter, compared to a net loss of $21.2 million or $0.64 per share in the same period last year.

On an adjusted basis, earnings were $21.97 million or $0.65 per share, compared to a loss of $20.45 million or $0.61 per share in the year ago quarter. On average, eight analysts polled by Thomson Reuters expected the company to earn $0.48 per share for the quarter. Analysts' estimates typically exclude special items.

Net income for the quarter included a one-time gain related to the acquisition of certain assets of MDRNA's Hauppauge, NY facility, while net loss a year ago included a one-time development milestone payment to a partner.

Total revenues for the quarter climbed to $404 million from $112.94 million last year. Analysts expected revenues of $232.87 million.

The company said that the recent quarter revenue increase was principally driven by the lack of competition in metoprolol succinate and meclizine, and the launches of sumatriptan injection and dronabinol in the second half of 2008.
Net sales of metoprolol succinate reached $306 million, an increase of 173% from the first quarter 2009. Par was the exclusive supplier of metoprolol succinate through the second quarter, and is supplies generic metoprolol succinate for all strengths of AstraZeneca's Toprol XL.

Net sales of sumatriptan injection were $21.8 million for the quarter, compared to $16.0 million in the first quarter.

Net sales from all other generic products were $39.6 million for the quarter, down from $43.0 million in the first quarter. The decrease primarily reflects the discontinuation ofof fluticasone and a decline in volume and price of certain products, including ibuprofen, due to continued competition in the market, tempered by an increase in volume of certain products such as tramadol APAP and fluoxetine HCl, as well as the launch of risperidone ODT in June 2009.

For the first half, the company reported net income of $39.9 million or $1.18 per share, compared to a net loss of $19.8 million or $0.60 per share in the same period of 2008. Adjusted net income was $37.4 million or $1.11 per share, compared to a loss of $15.91 million or $0.48 per share.

To receive FREE breaking news email alerts for Par Pharmaceutical Companies Inc and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
  Trading Center
 

More Breaking News-US

73  EU Extends Review Deadline For Oracle's Proposed Takeover Of Sun Micro - Update
72  Pfizer's Geodon Approved As Adjunctive For Bipolar Disorder - Update
71  CF Nominees Enter Terra's Board - Update
70  Archipelago Learning Prices IPO Within Expected Range; Stock Soars - Update
69  Brown University And IBM Launch Multimillion-Dollar Supercomputer - Update
68  GLG Life Tech Starts Trading On Nasdaq; Shares Down 13.7% - Update
67  Global Defense Technology Prices IPO At $13/Share, Below Prior Estimate - Update
66  Dendreon Gets FDA Acceptance For Prostrate Cancer Drug Application - Update
65  Covidien's Pain Drug NDA Review Extended By FDA - Update
64  Inovio's Pre-clinincal Study Of Universal Flu Vaccines Reports Protective Response Against Multiple Influenza Strains; Stock Up - Update
63  Cloud Peak Energy Prices IPO At $15/shr - Update
62  Met-Pro Q3 Profit Plunges - Update
61  Boston Scientific Receives FDA's 510 (k)Clearance For WallFlex Fully Covered Esophageal Stent - Update
60  Pfizer Granted FDA Approval For Intravenous Formulation Of Revatio - Update
59  Berkshire Hathaway Secures $8 Bln. For Burlington Northern Deal - Update
  

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS